224 related articles for article (PubMed ID: 14521495)
1. Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer's disease?
Doggrell S
Expert Opin Pharmacother; 2003 Oct; 4(10):1857-60. PubMed ID: 14521495
[TBL] [Abstract][Full Text] [Related]
2. Memantine in moderate-to-severe Alzheimer's disease.
Reisberg B; Doody R; Stöffler A; Schmitt F; Ferris S; Möbius HJ;
N Engl J Med; 2003 Apr; 348(14):1333-41. PubMed ID: 12672860
[TBL] [Abstract][Full Text] [Related]
3. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
[TBL] [Abstract][Full Text] [Related]
4. Memantine for dementia.
Areosa SA; Sherriff F
Cochrane Database Syst Rev; 2003; (3):CD003154. PubMed ID: 12917950
[TBL] [Abstract][Full Text] [Related]
5. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
[TBL] [Abstract][Full Text] [Related]
6. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors.
Grossberg GT; Manes F; Allegri RF; Gutiérrez-Robledo LM; Gloger S; Xie L; Jia XD; Pejović V; Miller ML; Perhach JL; Graham SM
CNS Drugs; 2013 Jun; 27(6):469-78. PubMed ID: 23733403
[TBL] [Abstract][Full Text] [Related]
7. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.
Peskind ER; Potkin SG; Pomara N; Ott BR; Graham SM; Olin JT; McDonald S
Am J Geriatr Psychiatry; 2006 Aug; 14(8):704-15. PubMed ID: 16861375
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
Wilkinson D; Andersen HF
Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
[TBL] [Abstract][Full Text] [Related]
9. [Mémantine (Ebixa): a new therapeutic strategy for the treatment of moderate to severe forms of Alzheimer's disease].
Gallarda T; Lôo H
Encephale; 2004; 30(1):69-79. PubMed ID: 15029079
[TBL] [Abstract][Full Text] [Related]
10. Lack of evidence for the efficacy of memantine in mild Alzheimer disease.
Schneider LS; Dagerman KS; Higgins JP; McShane R
Arch Neurol; 2011 Aug; 68(8):991-8. PubMed ID: 21482915
[TBL] [Abstract][Full Text] [Related]
11. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
Wilcock GK; Ballard CG; Cooper JA; Loft H
J Clin Psychiatry; 2008 Mar; 69(3):341-8. PubMed ID: 18294023
[TBL] [Abstract][Full Text] [Related]
12. Memantine for dementia.
Areosa SA; Sherriff F
Cochrane Database Syst Rev; 2003; (1):CD003154. PubMed ID: 12535459
[TBL] [Abstract][Full Text] [Related]
13. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials.
Winblad B; Jones RW; Wirth Y; Stöffler A; Möbius HJ
Dement Geriatr Cogn Disord; 2007; 24(1):20-7. PubMed ID: 17496417
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and comparison of the meta-analyses evaluating the efficacy of memantine in moderate to severe stages of Alzheimer's disease.
Rive B; Gauthier S; Costello S; Marre C; François C
CNS Drugs; 2013 Jul; 27(7):573-82. PubMed ID: 23765561
[TBL] [Abstract][Full Text] [Related]
15. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.
Dysken MW; Sano M; Asthana S; Vertrees JE; Pallaki M; Llorente M; Love S; Schellenberg GD; McCarten JR; Malphurs J; Prieto S; Chen P; Loreck DJ; Trapp G; Bakshi RS; Mintzer JE; Heidebrink JL; Vidal-Cardona A; Arroyo LM; Cruz AR; Zachariah S; Kowall NW; Chopra MP; Craft S; Thielke S; Turvey CL; Woodman C; Monnell KA; Gordon K; Tomaska J; Segal Y; Peduzzi PN; Guarino PD
JAMA; 2014 Jan; 311(1):33-44. PubMed ID: 24381967
[TBL] [Abstract][Full Text] [Related]
16. Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors.
Grossberg GT; Alva G; Hendrix S; Ellison N; Kane MC; Edwards J
Alzheimer Dis Assoc Disord; 2018; 32(3):173-178. PubMed ID: 29771687
[TBL] [Abstract][Full Text] [Related]
17. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil.
van Dyck CH; Schmitt FA; Olin JT;
Am J Geriatr Psychiatry; 2006 May; 14(5):428-37. PubMed ID: 16670247
[TBL] [Abstract][Full Text] [Related]
18. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
Lipton SA
J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
[TBL] [Abstract][Full Text] [Related]
19. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease.
Doody R; Wirth Y; Schmitt F; Möbius HJ
Dement Geriatr Cogn Disord; 2004; 18(2):227-32. PubMed ID: 15256834
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients.
Zhang N; Wei C; Du H; Shi FD; Cheng Y
Dement Geriatr Cogn Disord; 2015; 40(1-2):85-93. PubMed ID: 26066622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
